Lilong Pan received his Ph.D. in Pharmacology from Fudan University in 2011. After graduation, he remained at Fudan University School of Pharmacy as a lecturer. In 2017, he joined Wuxi Medical School, Jiangnan University, as an associate professor, and since June 2021, he has been a full professor. Professor Pan's research focuses on cardiovascular pharmacology and anti-inflammatory immunopharmacology, with a particular interest in the roles and mechanisms of gut microbiota metabolites and endogenous active substances in regulating immune inflammation in cardiovascular and pancreas-intestinal homeostasis. He has published a series of SCI papers in journals such as EMBO Mol Med (cover article), Allergy, Cardiovasc Res, Acta Pharm Sin B, Theranostics, Br J Pharmacol, BMC Med, and Pharmacol Res. He has received several awards, including the Servier Young Pharmacologist Award from the Chinese Pharmacological Society, the Third Prize of Sichuan Provincial Science and Technology Progress Award (2020), the Second Prize of Jiangsu Traditional Chinese Medicine Science and Technology Award (2020), the Second Prize of Shanghai Pharmaceutical Science and Technology Award (three times), and the Third Prize of the Chinese Pharmaceutical Association Science and Technology Award (2011). He has also contributed to the transfer of two Class 1 new drug achievements. Professor Pan serves as a committee member of the Anti-inflammatory Immunopharmacology Professional Committee and the Youth Work Committee of the Chinese Pharmacological Society, and the Anti-inflammatory Immunopharmacology Professional Committee of the Jiangsu Pharmacological Society. He is also an expert reviewer for the National Natural Science Foundation of China and serves as a reviewer for SCI journals such as Cell Rep Med and Br J Pharmacol. |
